ZUMA 7 Trial Summary Patients with early relapsed or refractory large B-cell lymphoma often face poor prognoses after receiving first-line chemoimmunotherapy. However, a recent international, phase 3 trial has demonstrated promising results with the use of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy. In this trial, patients with large B-cell lymphoma, […]
Category: Hematology
ANT 005 TKA Trial: Abelacimab for VTE
2021 ANT-005 TKA TRIAL M Abelacimab for Prevention of Venous Thromboembolism (VTE) Phase 2,open-label, prospective randomized trial 400 Objective: To compare the efficacy & safety of abelacimab administered postoperatively with the efficacy & safety of enoxaparin in patients undergoing total knee arthroplasty. patients Inclusion criteria: Patients 18 to 80 years of age undergoing elective […]
AMPLIFY Trial: Apixaban for acute VTE
2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis Inclusion criteria: Patients ≥18 years with symptomatic VTE, 5,395 either DVT proximal to popliteal vein […]
AXIOMATIC-TKR Trial Summary: Milvexian for the Prevention of VTE
2022 AXIOMATIC-TKR TRIAL Milvexian for the prevention of Venous thromboembolism Parallel-group, Open-label, randomized controlled trial Objective: To compare the efficacy & safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty 1242 patients INCLUSION CRITERIA: Patients undergoing unilateral total knee arthroplasty greater than 50 years of age without contraindicatior to enoxaparin or history of […]